Emily E. Bosco: AstraZeneca will be presenting 14 abstracts in cancer immunotherapy at SITC 2024
Emily E. Bosco, Senior Director in Cell Therapy, Early oncology at AstraZeneca, shared on LinkedIn:
“At SITC 2024, AstraZeneca will be presenting 14 abstracts that demonstrate our progress in cancer immunotherapy.
A highlight will be the sharing of preclinical data from our novel Target Induced T cell Activating Nanobody (TITAN) platform, including the first disclosure of a TITAN T-cell engager intended for use in solid tumours.
Recent advances in our understanding of the immune system are driving the development of the next generation of immunotherapies, and we’re pushing the boundaries of science to reimagine cancer care and help transform outcomes for patients.
Find out more our focus areas in immunotherapy here.”
More posts featuring AstraZeneca on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023